Olaparib (Lynparza) for metastatic breast cancer with germline BRCA mutation – second line
NIHR HSRIC
Record ID 32016000520
English
Authors' recommendations:
Breast cancer is the most common cancer in the UK. BRCA genes make proteins that help repair damaged DNA. Women with a BRCA gene mutation have a much higher risk of breast and other cancers. Most women who get breast cancer are over 50 years of age. However, people that have a breast cancer with BRCA gene mutation often get it at a younger age.
Olaparib is a new treatment for breast cancer with germline BRCA mutation that can be taken by mouth as a capsule. Some studies have suggested olaparib may be helpful for people whose first chemotherapy treatment has failed and more studies are now aiming to show how well it works and that it is safe to use.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/olaparib-lynparza-for-metastatic-breast-cancer-with-germline-brca-mutation-second-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Antineoplastic Agents
- Breast Neoplasms
- Enzyme Inhibitors
- Mutation
- Phthalazines
- Piperazines
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.